Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1810 results
August 2022
-
StatementBranaplam : VIBRANT-HD Study Update
-
Key ReleaseNovartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-offAd hoc announcement pursuant to Art. 53 LR Sandoz strategic review concludes that a separation of Sandoz by way of a 100% spin-off is in the best interest of shareholders, creating the…
-
Key Release
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
Ad-hoc-Mitteilung gemäss Art. 53 KR Die strategische Überprüfung von Sandoz hat ergeben, dass eine Abspaltung von Sandoz durch eine hundertprozentige Ausgliederung im besten Interesse… -
Media ReleaseNovartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancerPhase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1Findings will be…
-
StatementZolgensma acute liver failure update
July 2022
-
Media ReleaseApplications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMASubmission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EUMultiple sclerosis (MS) is a chronic inflammatory…
-
Featured NewsFrom the Heart
-
Media ReleaseSandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with chronic…
-
Key ReleaseNovartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidanceAd hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%…
-
Key Release
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz stieg im zweiten Quartal um +5% kWk1 (–1% USD) Innovative Medicines (IM) steigerte den Umsatz um +5% kWk (–1% USD); starke Performance der… -
Key Release
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe
Annonce événementielle au sens de l’art. 53 RC Chiffre d’affaires du T2 en hausse de +5% tcc1 (-1% USD) Innovative Medicines (IM): hausse du chiffre d’affaires de +5% (tcc, -1% USD), avec… -
Featured NewsNovartis Financial Results – Q2 2022
Novartis announced the company’s financial results for the second quarter and first half of 2022.
Pagination
- ‹ Previous page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- …
- 151
- › Next page